List view / Grid view
Within cancer cells, the eIF4F complex's dysregulation amplifies the translation of cancer-promoting proteins, establishing it as a critical juncture in malignancy and resistance to treatment. eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance…
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
Discovery about the DNA of leukaemia cells suggests promising target for gene therapy in paediatric oncology.
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and…
Researchers have developed organoids with naturally occurring early-stage immune cells, which could lead to effective personalised treatment.
Eliminating AT1-like cells in experimental models has shown potential to improve KRAS inhibitor treatment for lung adenocarcinoma.
Using the nicotinamide mononucleotide molecule led to proliferation of non-senescent macrophages and lessened immunosuppressive factors.
Researchers have developed an AI based model that is 80 percent accurate in predicting the therapy outcome of high-grade ovarian cancer.
Cellulose nanofiber sheets enable analysis of EVs, and miRNAs within them, offering potential for cancer treatment and personalised medicine.
Cell therapies hold great potential for treating complex diseases, yet they face significant limitations and challenges. Current cell therapies have difficulty distinguishing between healthy and cancerous cells, often resulting in adverse effects. Vittoria's innovative Senza5 platform, with its unique CD5-targeting approach, aims to enhance the efficacy, safety, and speed of…
Analysis of cells shows many regions in DNA are differentially activated or inactivated in a cancer-specific manner.
Scientists have discovered the motor protein dynein commands movement of cancer cells in soft tissue models, offering new clinical targets.
Researchers have found that reducing glycosylation on the T cell surface may offer new approaches to cancer immunotherapy.
Researchers have discovered a molecule that binds to a cancer cell protein, stopping growth of breast and ovarian tumours.
An epitope on CD95 receptor causes tumour cells to self-destruct and may prolong benefits of CAR T-cell therapy for solid tumours.
